Introduction {#Sec1}
============

Diabetes mellitus is associated with slowly progressive changes in the brain \[[@CR1]\]. Neuropsychological studies show that patients with type 2 diabetes mellitus have mild to moderate impairments in attention and executive functioning, information processing speed and memory (for reviews see \[[@CR2], [@CR3]\]). Patients with type 2 diabetes also show changes on brain magnetic resonance imaging (MRI), such as cortical and hippocampal atrophy \[[@CR4], [@CR5]\]. We have recently shown that cognitive dysfunction in patients with type 2 diabetes was associated with white matter lesions (WML), (silent) brain infarcts and to a lesser extent with atrophy \[[@CR6]\].

The determinants of changes in cognition and abnormalities on brain MRI of patients with type 2 diabetes are uncertain \[[@CR2]\]. Some studies report associations with hypertension \[[@CR3], [@CR4], [@CR7], [@CR8]\], but this was not supported by others \[[@CR5], [@CR9], [@CR10]\]. Associations between impaired cognition and chronic hyperglycaemia have also been noted \[[@CR9]\]. Studies on other diabetic complications may provide leads for potentially relevant determinants. Complications like nephropathy, retinopathy and neuropathy are thought to be due to hyperglycaemia-induced microangiopathy \[[@CR11], [@CR12]\], with additional involvement of hypertension and macrovascular disease \[[@CR13]--[@CR15]\]. Since atherosclerosis and hypertension are established risk factors for age-related cognitive decline and brain MRI changes in the general population \[[@CR16]--[@CR19]\], we hypothesised that the combined effects of atherosclerotic macrovascular disease, chronic hyperglycaemia and hypertension are involved in the development of cognitive impairments in patients with type 2 diabetes.

The aim of the present study was to identify possible metabolic and vascular determinants of cognitive dysfunction and changes on brain MRI in patients with type 2 diabetes. Given the uncertainty about these determinants, an exploratory design was chosen. A detailed neuropsychological examination and brain MRI were obtained from a large cross-sectional sample of type 2 diabetes patients and related to different measures of glucose metabolism, vascular risk factors, microvascular complications and macrovascular disease.

Methods {#Sec2}
=======

**Participants** The Utrecht Diabetic Encephalopathy Study aims to identify determinants of cognitive impairment in patients with diabetes \[[@CR6]\]. Therefore, patients were not selected for the presence or absence of diabetic complications, co-morbid conditions (e.g. hypertension) or exposure to other risk factors (e.g. smoking). For inclusion patients had to be 55 to 80 years of age, functionally independent and speakers of Dutch, with a minimal diabetes duration of 1 year. Exclusion criteria for all participants were: a psychiatric or neurological disorder that could influence cognitive functioning; a history of alcohol or substance abuse and dementia; and, for the control group, a fasting blood glucose ≥7.0 mmol/l \[[@CR20]\]. Participants with a history of stroke who were still fully functionally independent were classified as eligible. To increase statistical power for within-group analyses in the type 2 diabetes group, twice as many patients as controls were enrolled.Overall, 122 patients with type 2 diabetes (age 56--80 years) and 56 controls (age 57--78 years) were included in the present study. Patients were recruited through their general practitioners; controls were spouses or acquaintances of the patients. Groups were comparable for age, sex and educational level. The study was approved by the local medical ethics committee and each participant signed an informed consent form. All participants underwent a 2 day protocol, which included brain MRI, a neurological and neuropsychological examination, retinal photography and ultrasonography of the carotid arteries. Fasting blood and urine samples were collected and blood pressure was recorded. In one control person and two type 2 diabetes patients it was not possible to perform the neuropsychological examination. Similarly, MRIs could not be obtained in five controls and nine type 2 diabetes patients, mostly due to MRI contraindications (claustrophobia, pacemaker).

**Neuropsychological examination** The neuropsychological examination tapped the major cognitive domains in verbal and non-verbal ways. Eleven tasks were administered in a fixed order, taking about 90 min to complete. These tasks were divided into five cognitive domains, as described previously \[[@CR6]\]: (1) attention and executive functioning; (2) information processing speed; (3) memory; (4) abstract reasoning; and (5) visuoconstruction. For analysis the test scores were standardised into *z* scores for each of the five domains, based on the means of the whole group. The mean performance from each participant across the domains is expressed as the composite cognitive *z* score.Premorbid IQ was assessed with the Dutch version of the National Adult Reading Test. To control for possible effects of mood disturbances or affective disorders a Beck depression inventory \[[@CR21]\] was performed.

**Brain MRI** The MRI investigation (1.5 T; Philips Medical Systems, Best, the Netherlands) consisted of an axial T1-weighted and an axial T2 and T2 fluid-attenuating inverse recovery (FLAIR) scan (TR/TE/TI: 6000/100/2000, field of view 230 mm, matrix 180 × 256, slice thickness 4.0 mm, contiguous, 38 slices).WML were rated according to the Scheltens scale \[[@CR22]\] with slight modifications \[[@CR6]\]. Periventricular WML (PWML) were rated on a severity scale (0--2) at the frontal and occipital horns and the body of the lateral ventricle on both sides (sum score 0--12). For the rating of deep (subcortical) WML (DWML) the brain was divided into six regions: frontal, parietal, occipital, temporal, basal ganglia and infra-tentorial. Per region the size and number of WML were rated on a scale ranging from 0 to 6. The total score thus ranged from 0 to 36.Cortical atrophy was evaluated by the frontal interhemispheric fissure ratio and the Sylvian fissure ratio \[[@CR23]\]. Subcortical atrophy was evaluated by the bifrontal ratio and by the bicaudate ratio \[[@CR23]\]. These ratios were converted to *z* scores: a cortical atrophy *z* score (mean of *z* frontal fissure ratio and *z* Sylvian fissure ratio) and a subcortical atrophy *z* score (mean of *z* bicaudate ratio and *z* bifrontal ratio).All MRI scans were rated by two investigators (S. M. Manschot and G. J. Biessels) blinded for presence or absence of diabetes or other characteristics. In case of disagreement of more than 1 point on the WML scales in a particular region or more than 5 mm (actual size) on any of the atrophy measurements (2 mm for fissure widths), a consensus reading was held (0% of PWML, 4% of DWML and 4% of atrophy ratio readings were thus affected). In all other cases the readings of both raters were averaged.

**Diabetes characteristics and glucose metabolism** A standardised questionnaire addressed medical history, medication use, diabetes duration and the life-time occurrence of severe hypoglycaemic episodes (defined as episode of hypoglycaemia severe enough to require the assistance of another person, hospitalisation or emergency room visit). BMI was calculated as weight divided by height square.Blood was drawn by venepuncture to assess HbA~1c~, fasting glucose and insulin levels. Insulin resistance was estimated with the homeostasis model assessment of insulin resistance (HOMA-IR). The HOMA-IR is calculated as fasting glucose (mmol/l) × fasting insulin (mU/l)/22.5 \[[@CR24]\]. Because insulin was expressed in pmol/l we used the formula fasting glucose (mmol/l) × fasting insulin (pmol/l)/(22.5 × 6.945) \[[@CR24]\].

**Vascular risk factors** Blood pressure was measured at home at nine fixed time points during the day with an automatic blood pressure machine (705CP; Omron, Mannheim, Germany). These measurements were averaged. In the primary analysis hypertension was defined as a mean systolic blood pressure \>160  mmHg or a mean diastolic pressure \>95 mmHg or the use of antihypertensive medication. In a second analysis cut-off values for systolic and diastolic blood pressure of 140 and 90 mmHg were used.Smoking habits were classified as 'current' and 'past or never'. Total cholesterol, HDL-cholesterol, LDL-cholesterol and triacylglycerol were assessed in a fasting venous blood sample.

**Microvascular disease** Following mydriasis with phenylephrine and tropicamide, single-field photographs were taken of both eyes with a 50-degree retinal camera (Zeiss FF 450, Carl Zeiss B.V., Sliedrecht, the Netherlands), centred on the macula. Retinopathy was rated on slides, according to the diabetic retinopathy severity scale (grades 1--7) as used in the Wisconsin Epidemiologic Study of Diabetic Retinopathy \[[@CR25]\]. Photocoagulated eyes were rated at grade 5 or higher (severe non-proliferative diabetic retinopathy). Ratings were performed by two investigators, blinded to patient characteristics. In case of disagreement (2%), a third investigator was involved and a consensus was made. Retinopathy was defined as a grade of 1.5 or higher.Neuropathy was rated with the Toronto Clinical Neuropathy Scoring System \[[@CR26]\], with a slight modification. A sensory test for temperature was not performed, so that the maximum score was 18 points (severe polyneuropathy) instead of 19. A score of 0--5 indicated no neuropathy, 6--8 indicated mild neuropathy, 9--11 moderate neuropathy and ≥12 severe neuropathy. Neuropathy was defined as a score of ≥6.Urine was collected overnight. Albuminuria was defined as microalbuminuria (albumin 0.03--0.25 g/l) or macroalbuminuria (albumin 0.25 g/l or positive protein dipstick test).

**Macrovascular disease** Several composite measures of macrovascular disease were defined. 'Any peripheral arterial disease' was defined as current complaints of intermittent claudication (assessed with the Rose questionnaire \[[@CR27]\]) or a history of surgery or endovascular treatment for arterial disease of the legs or the abdominal aorta. 'Ischaemic heart disease' was defined as a history of myocardial infarction or surgery or endovascular treatment for coronary artery disease. 'Any vascular event' was defined as a history of myocardial infarction or stroke, or a history of operative or endovascular treatment for coronary, carotid or peripheral (legs, abdominal aorta) artery disease.Brain infarcts were rated on brain MRI, by location (cortical and subcortical), size (lacunar \[\<1.5 cm\] or large) and number. A lesion was considered an infarct if it was hypo-intense on T1 and FLAIR images and if its appearance was unlike a perivascular space.Carotid intima-media thickness (CIMT) was measured in both common carotid arteries as described previously \[[@CR28]\] with an ATL Ultramark 9 (Advanced Technology Laboratories, Bothell, WA, USA) equipped with a 10-MHz linear-array transducer. Scanning was performed at three different longitudinal projections (anterior-oblique, lateral and posterior-oblique). The CIMT was measured in a 1 cm section proximal to the beginning of the dilatation of the carotid bulb in all three projections, in both carotid arteries. CIMT was calculated as the average of these six measurements. CIMT readings were not available in six type 2 diabetes patients and one person in the control group.

**Statistical analysis** The differences between patients and the control group were examined with *t* test for means, Mann--Whitney *U* was used for non-parametric data and χ^2^ test for proportions. In the text and tables, data are shown as mean ± SD or proportions, unless stated otherwise.Within the type 2 diabetes population, cognition (five domains) and brain MRI findings (cortical and subcortical atrophy *z* scores, PWML, DMWL and infarcts) were related to the different measures of glucose, insulin and lipid metabolism, and to microvascular complications and macrovascular disease by linear or logistic regression analyses, adjusting for age, sex and estimated IQ. In order to limit the number of analyses the 'composite cognitive *z* score' was used as the primary cognitive outcome measure in the regression analyses. For significant associations, post hoc tests were performed per domain. Secondary analyses were performed with information processing speed, the domain most markedly affected by type 2 diabetes. The results were essentially the same as for the composite cognitive *z* score (data not shown).In the regression analyses, B values \>0 indicate that a variable is associated with more severe MR abnormalities; for cognition B values \<0 indicate that a variable is associated with more pronounced performance impairments. For the between and within-group analyses, *p* \< 0.05 was considered statistically significant. All variables that reached a significance level of *p* ≤ 0.1 in the adjusted univariate risk factor analyses were included in a multivariate model that also included age, sex and estimated IQ.

Results {#Sec3}
=======

**Participant characteristics** The age, sex, level of education and estimated IQ in the groups were comparable (Table [1](#Tab1){ref-type="table"}). Table 1Participant characteristicsCharacteristicType 2 diabetes groupControl groupParticipants (*n*)12256Sex (male/female)62/6025/31Age (years)66.0 ± 5.865.1 ± 5.2Level of education (1--7)^a^4 (3--5)4 (3--5)Estimated premorbid IQ99 ± 15101 ± 14Diabetes duration (years)^b^8.7 ± 6.1Diabetes treatment (%) Diet10 Oral medication alone61 Insulin^b^29HbA~1c~ (%)^b^6.9 ± 1.2\*\*^,\ d^5.5 ± 0.3Fasting glucose levels (mmol/l)^b^8.6 ± 2.9\*\*5.5 ± 0.6Fasting insulin levels (pmol/l)^b,c^120 ± 110\*\*^,\ e^ (*n* = 82)76 ± 50 (*n* = 54)HOMA-IR^b,c^6.6 ± 6.4\*\*^,\ f^2.6 ± 1.8BMI (kg/m^2^)^b^28.1 ± 4.427.3 ± 5.3Data are given as number or percentage (as indicated), mean ± SD or ranges\*\**p* \< 0.01 for type 2 diabetes vs control group^a^Level of education was expressed in seven categories \[[@CR49]\]^b^Entered as explanatory variable in the regression analyses within the type 2 diabetes group^c^Only from participants who were not treated with insulin and did not have antibodies against insulinStatistically significant associations within the type 2 diabetes group: with composite cognitive *z* scores---^d^*p* \< 0.05; with MRI abnormalities---^e^*p* \< 0.01, ^f^*p* \< 0.05Detailed neuropsychological and MRI data have been reported previously \[[@CR6]\]. In short, performance of patients with type 2 diabetes was worse than that of the control group across all five cognitive domains, with statistically significant differences on attention and executive functioning (difference mean *z* scores 0.23 \[95% CI 0.03, 0.43\]; *p* = 0.02), information processing speed (0.40 \[0.17, 0.63\]; *p* = 0.001) and memory (0.20 \[0.05, 0.36\]; *p* = 0.01). Patients with type 2 diabetes had more pronounced cortical atrophy (difference mean *z* scores 0.62 \[95% CI 0.33, 0.91\]; *p* \< 0.001) and subcortical atrophy (0.38 \[0.07, 0.68\]; *p* = 0.01). They also had more severe DWML (controls, median \[range\]: 5 \[0, [@CR18]\]; type 2 diabetes: 7 \[0.5, 27.5\]; *p* = 0.02), but PWML severity in the two groups was similar (control: 6 \[[@CR4], [@CR10]\]; type 2 diabetes: 6 \[[@CR3], [@CR12]\]; *p* = 0.13). Patients with type 2 diabetes also had more (silent) cerebral infarcts than controls (type 2 diabetes 22/113, control 4/54; *p* = 0.06).

**Glucose metabolism** HbA~1c~, fasting glucose and insulin levels were higher (all *p* \< 0.01) in patients with type 2 diabetes than in the control group. BMI was similar in both groups. Only a small proportion (6%) of type 2 diabetes patients had ever experienced a severe hypoglycaemic event (Table [1](#Tab1){ref-type="table"}).In the regression analyses within the type 2 diabetes group, HbA~1c~ levels were significantly related to cognition (composite *z* score: B \[per % HbA~1c~\]: −0.07 \[−0.14, 0\] *p* = 0.047; post hoc per domain: information processing speed: B \[per % HbA~1c~\]: −0.15 \[95% CI: −0.27, −0.2\], *p* = 0.02; abstract reasoning: B: −0.15 \[−0.29, −0.01\], *p* = 0.04). Elevated fasting insulin levels and HOMA-IR were related to increased DWML severity (B \[per 10 pmol/l insulin\]: 0.14 \[0.04, 0.26\], *p* = 0.009; B \[HOMA-IR\]: 0.21 \[0.04, 0.39\], *p* = 0.02).

**Vascular risk factors** Table [2](#Tab2){ref-type="table"} shows that patients with type 2 diabetes had higher systolic blood pressure (*p* \< 0.01) and pulse pressure (*p* \< 0.05) than controls. They also had hypertension more often (*p* \< 0.01). Total cholesterol was lower in the type 2 diabetes group (*p* \< 0.01), but the proportion of individuals taking lipid-lowering drugs was higher in that group (*p* \< 0.01). There were no statistically significant differences between type 2 diabetic patients and the control group in the proportion of participants who smoked or had dyslipidaemia (Table [2](#Tab2){ref-type="table"}). Table 2Vascular risk factorsCharacteristicType 2 diabetes group (*n* = 122)Control group (*n* = 56)Mean arterial pressure (mmHg)^a^103 ± 11\*,^b^98 ± 10Pulse pressure (mmHg)^a^65 ± 15\*59 ± 16Hypertension (%)^a^73\*\*34Antihypertensive drugs (%)70\*\*32Current smoking (%)^a^2214Total cholesterol (mmol/l)^a^5.0 ± 0.9\*\*5.8 ± 1.1HDL-cholesterol (mmol/l)^a^4.3 ± 1.24.4 ± 1.5Triacylglycerol (mmol/l)^a^1.9 ± 1.01.6 ± 1.1Lipid-lowering drugs (%)^a^54\*\*,^c^21Data are given as percentage or mean ± SD\**p* \< 0.05, \*\**p* \< 0.01 for type 2 diabetes vs control group^a^Entered as explanatory variable in the regression analyses within the type 2 diabetes group^b^*p* \< 0.05 for association with more severe MRI abnormalities^c^*p* \< 0.05 for reverse associationIn the regression analyses within the type 2 diabetes group there were no statistically significant associations with the composite cognitive *z* score. Non-significant trends (*p* ≤ 0.10) were observed for associations between both hypertension and current smoking and impaired cognitive performance (hypertension B: −0.19 \[−0.38, 0\], *p* = 0.053; smoking B: −0.21 \[−0.43, 0\], *p* = 0.051), and between the use of lipid-lowering drugs and better performance (B: 0.15 \[−0.03, 0.32\], *p* = 0.10). Reanalysis with cut-off values for hypertension of 140/90 mmHg made the association with the composite cognitive *z* score less strong. Mean arterial pressure was associated with more severe PWML (B \[per 10 mmHg\]: 0.28 \[0.03, 0.53\], *p* = 0.03). The use of lipid-lowering drugs (statins in all but one patient) was associated with less severe MRI abnormalities (PWML: B: −0.68 \[−1.25, −0.12\], *p* = 0.02; cortical atrophy: B: −0.36 \[−0.69, −0.03\], *p* = 0.03). These effects were not affected by additional adjustment for the actual cholesterol levels (Table [2](#Tab2){ref-type="table"}).

**Microvascular disease** In 20 patients with type 2 diabetes and 8 control individuals it was not possible to perform retinal photographs. Mostly due to logistical reasons, overnight urine samples could not be obtained from 21 diabetic patients and 13 controls. Patients with type 2 diabetes had more retinopathy and neuropathy than the control group (both *p* \< 0.01). Although albuminuria was more common in the type 2 diabetic than in the control group, this difference was not statistically significant (Table [3](#Tab3){ref-type="table"}). Table 3Microvascular diseaseCharacteristicType 2 diabetes group (*n* = 122)Control group (*n* = 56)Retinopathy (diabetes *n* = 112; control *n* = 48)^a^37 (33)\*\*^,b^1 (2) Background331 Severe non-proliferative4Neuropathy^a^47 (39)\*\*7 (13) Mild neuropathy257 Moderate neuropathy180 Severe neuropathy40Albuminuria (diabetes *n* = 101; control *n* = 43)^a^16 (16)3 (7) Microalbuminuria93 Macroalbuminuria70Any microvascular disease^c^72 (59)\*\*11 (20)Data are given as values (percentage)\*\**p* \< 0.01 for type 2 diabetes vs control group^a^Entered as explanatory variable in the regression analyses within the type 2 diabetes group^b^*p* \< 0.05 for association with MRI abnormalities^c^Includes all patients with albuminuria, neuropathy or retinopathyIn the regression analyses within the type 2 diabetes group, there were no statistically significant associations with the composite cognitive *z* score. Retinopathy was associated with more pronounced cortical atrophy (B: 0.48 \[0.11, 0.85\], *p* = 0.01) (Table [3](#Tab3){ref-type="table"}).

**Macrovascular disease** Patients with type 2 diabetes were more likely to have had intermittent claudication (*p* \< 0.01) or a history of ischaemic heart disease (*p* \< 0.01). There was no difference between the two groups in the CIMT (Table [4](#Tab4){ref-type="table"}). Table 4Macrovascular diseaseCharacteristicType 2 diabetes group (*n* = 122)Control group (*n* = 56)Any peripheral arterial disease^a^18 (15)\*\*0 Claudicatio intermittens14 (11)\*\*0 Vascular surgery femoral artery4 (3)0 Vascular surgery (AAA)3 (3)0Ischaemic heart disease^a^23 (19)\*\*^,b^2 (4) Myocardial infarction15 (12)\*1 (2) CABG13 (11)\*1 (2)Brain infarct on MRI^a^22 (20)\*^,b,c^4 (8)History of brain infarct^a^7 (6)2 (4)Carotid surgery^a^2 (2)1 (2)Any vascular event ^a^33 (27)\*\*^,b,c^4 (7)CIMT^a^0.093 ± 0.0180.092 ± 0.023Data are given as value (percentage) or mean ± SDAAA, abdominal aortic aneurysm; CABG, coronary artery bypass grafting\**p* \< 0.05, \*\**p* \< 0.01 for type 2 diabetes vs control group^a^Entered as explanatory variable in the regression analyses within the type 2 diabetes groupStatistically significant associations: with MRI abnormalities ^b^*p* \< 0.05; with impaired cognition ^c^*P* \< 0.05In the regression analyses within the type 2 diabetes group, a history of 'any vascular event' and the presence of brain infarcts on MRI were associated with an impaired composite cognitive *z* score as follows: (1) vascular event: composite *z* score B: −0.25 (−0.44, −0.05), *p* = 0.01; post hoc per domain: information processing speed B: −0.46 (−0.80, −0.12), *p* = 0.008; and memory B: −0.23 (−0.41, −0.06), *p* = 0.01; (2) infarct on MRI: composite *z* score B: −0.28 (−0.50, −0.06), *p* = 0.01; post hoc per domain: information processing speed B: −0.77 (−1.14, −0.39), *p* \< 0.001; and abstract reasoning B: −0.41 (−0.82, 0.01), *p* = 0.06. A history of 'any vascular event' was also associated with more pronounced DWML (B: 2.0 \[0, 4.1\], *p* = 0.05) and with an increased occurrence of infarcts on MRI (odds ratio: 2.9 \[1.1, 7.9\], *p* = 0.04). Patients with a (silent) infarct on MRI tended to have more pronounced PWML (B: 0.7 \[0, 1.4\], *p* = 0.06) and cortical atrophy (B: 0.51 \[0.10, 0.92\], *p* = 0.02) relative to type 2 diabetes patients without infarcts on MRI (Table [4](#Tab4){ref-type="table"}).Exclusion of patients with a history of stroke attenuated the association between 'any vascular event' and the cognitive *z* score, but not that between 'any vascular event' and DWML.

**Multivariate analysis** For the majority of risk factors the values of the standardised regression coefficients ß were similar in the single risk factor and multivariate models, indicating that interaction between factors was limited. Values for ß for individual factors varied between 0.15 and 0.30, indicative of modest associations (Table [5](#Tab5){ref-type="table"}). Table 5Multivariate risk factor analyses within the type 2 diabetes group Single factors β (95% CI)Full model β (95% CI)Final model β (95% CI)Cognition Age−0.30 (−0.44, −0.16)\*\*\*−0.29 (−0.43, −0.14)\*\*\* Sex−0.12 (−0.24, 0.02) Estimated IQ0.65 (0.50, 0.79)\*\*\*0.65 (0.50, 0.80)\*\*\* HbA~1c~−0.14 (−0.28, −0.002)\*−0.11 (−0.25, 0.02) Hypertension−0.14 (−0.26, 0.002)−0.12 (−0.26, 0.01)−0.14 (−0.27, −0.001)\* Current smoking−0.14 (−0.29, 0.001)−0.15 (−0.29, −0.02)\*−0.14 (−0.27, 0.001) Lipid-lowering drugs0.12 (−0.02, 0.26)0.17 (0.03, 0.31)\*0.17 (0.03, 0.31)\* Any vascular event−0.18 (−0.32, −0.03)\*−0.18 (−0.32, −0.03)\*−0.19 (−0.34, −0.05)\*\* Brain infarct on MRI ^a^−0.18 (−0.32, −0.04)\*Cortical atrophy Sex−0.005 (−0.23, 0.22) Age0.35 (0.18, 0.52)\*\*\*0.34 (0.18, 0.51)\*\*\* Estimated IQ−0.07 (−0.24, 0.10) Lipid-lowering drugs−0.20 (−0.37, −0.02)\*−0.19 (−0.36, −0.03)\*−0.18 (−0.35, −0.02)\* Retinopathy0.24 (0.05, 0.43)\*0.21 (0.04, 0.39)\*0.22 (0.06, 0.39)\*\* Brain infarct on MRI0.22 (0.04, 0.39)\*0.23 (0.06, 0.40)\*\*0.23 (0.06, 0.40)\*\*DWML Sex0.13 (−0.05, 0.30) Age0.20 (0.02, 0.35)\*0.22 (0.04, 0.39)\* Estimated IQ−0.14 (−0.31, 0.04) Insulin level0.29 (0.08, 0.51)\*\*0.26 (0.04, 0.47)\*0.24 (0.03, 0.45)\* Any vascular event0.19 (−0.002, 0.37)0.15 (−0.03, 0.34)PWML Sex0.16 (−0.02, 0.34)0.16 (−0.02, 0.34) Age0.25 (0.07, 0.43)\*\*0.24 (0.07, 0.42)\*\* Estimated IQ−0.12 (−0.30, 0.06) Mean arterial pressure0.20 (0.02, 0.38)\*0.15 (−0.03, 0.33)0.17 (−0.004, 0.35) Lipid-lowering drugs−0.22 (−0.35, −0.001)\*−0.20 (−0.38, −0.02)\*−0.18 (−0.35, 0.001)\* Brain infarct on MRI0.17 (−0.006, 0.35)0.18 (0.01, 0.36)\*0.18 (0.009, 0.36)\**β* is the standardised regression coefficient *B*. The first column contains the values of *β* for all variables that reached a significance level of a least *p* = 0.10 in the univariate risk factor analyses within the type 2 diabetes patient group, adjusted for age, sex and estimated IQ. These variables were included in a multivariate model that also included age, sex and estimated IQ (second column, full model). The final model (third column) is based on backward elimination of non-significant factors. This final model shows which variables that were related to the outcome measures in the univariate model remained significantly associated with the outcome measures independently of the other factors in the full modelFor cognition *β* values \<0 indicate that a variable is associated with more pronounced performance impairments; for MRI *β* values \>0 indicate that a variable is associated with more severe MRI abnormalities\**p* \< 0.05\*\**p* \< 0.01\*\*\**p* \< 0.001^a^Because 'infarct on MRI' and 'history of any vascular event' were interrelated in the univariate analyses (see Macrovascular disease section) only 'history of any vascular event' was entered in the multivariate modelIn the multivariate model, hypertension and a history of vascular events were associated with worse cognitive performance and statin use with better performance. Retinopathy and brain infarction on MRI were associated with more severe cortical atrophy and statin use with less atrophy. A higher insulin level was associated with more DWML, brain infarction on MRI with more PWML and statin use with less PWML. Overall, macrovascular disease (history of macrovascular events or infarct on MRI) were most consistently associated with the different outcome measures (Table [5](#Tab5){ref-type="table"}).

Discussion {#Sec4}
==========

Patients with type 2 diabetes had more cortical and subcortical atrophy and more DWML than control participants and their overall performance in the five cognitive domains was worse. As expected, patients with type 2 diabetes had more microvascular complications, more macrovascular (atherosclerotic) disease and more hypertension than the control group. In multivariate regression analyses within the type 2 diabetes group, hypertension and a history of vascular events were associated with worse cognitive performance, while statin use was associated with better performance. Retinopathy and brain infarcts on MRI were associated with more severe cortical atrophy and statin use with less atrophy. Insulin level and brain infarcts were associated with more severe WML and statin use with less severe WML.

Cognitive function in patients with type 2 diabetes has been studied extensively (for reviews see \[[@CR2], [@CR3]\]). Performance in the domains verbal memory and information processing speed, and probably also executive functioning and non-verbal memory, is moderately impaired. Our results are in keeping with these findings. Thus far, relatively few studies have specifically addressed brain MRI abnormalities in patients with type 2 diabetes. In agreement with our observations, modest cortical and subcortical atrophy and symptomatic or asymptomatic infarcts have been found more often in type 2 diabetes patients than in control individuals \[[@CR4], [@CR5], [@CR29]\]. Results of previous studies on the association between type 2 diabetes and WMLs are less consistent \[[@CR30]\]. This might be due to the study populations involved and the use of relatively insensitive WML rating scales \[[@CR30]\].

Chronic hyperglycaemia might be a determinant of cerebral changes in patients with type 2 diabetes. In the present study, HbA~1c~ levels were related to the composite cognitive *z* score, but only in de univariate analysis. Moreover, retinopathy, which is generally considered to be a consequence of chronic exposure to hyperglycaemia \[[@CR11]\], was related to cortical atrophy. Previous studies on cognition in patients with type 2 diabetes have also reported an association with HbA~1c~ levels \[[@CR2], [@CR9], [@CR31]\]. The relation with fasting blood glucose or duration of diabetes is, however, inconsistent \[[@CR31], [@CR32]\]. No previous studies have provided detailed data on the association between glycaemic control and MRI changes in type 2 diabetes. Studies in type 1 diabetes mellitus, however, have shown an association between diabetic retinopathy (as a proxy of chronic hyperglycaemia) and both brain atrophy \[[@CR33], [@CR34]\] and cognitive functioning \[[@CR35]\]. There are no previous studies on the relation between insulin levels and cerebral complications in type 2 diabetes. The association with WML severity, observed by us in the present study, is of particular interest in the light of recent studies in the general population, which link insulin to vascular abnormalities and degenerative changes in the brain \[[@CR36], [@CR37]\].

Previous studies in the general population indicate that risk factors for vascular disease, such as hypertension, dyslipidaemia, increased BMI and smoking, are associated with an increased risk of cognitive decline and dementia and with brain MRI changes, including WML (e.g. \[[@CR38]--[@CR41]\]). Previous studies on the modulating effect of hypertension on cognitive function in type 2 diabetes show conflicting results \[[@CR7], [@CR9], [@CR42], [@CR43]\]. In the present study, hypertension was related with impaired cognitive performance and mean arterial pressure with PWML severity. To our knowledge, the relation between other vascular risk factors and both cognition and brain MRI in patients with type 2 diabetes has not been examined previously. The reverse association between the use of statins and both cognition and MRI findings is intriguing. Nevertheless, this observation cannot be regarded as proof of a possible treatment effect. It should be noted that the association between statin use and both cognition and age-related brain MRI changes in the general population is still being debated \[[@CR44]\]. The present findings will need to be confirmed by further studies.

Macrovascular atherosclerotic disease appeared to be the most consistent determinant of impaired cognition and brain MRI abnormalities in the type 2 diabetes patients in the present study. We have not found any previous studies that presented detailed data on the relation between macrovascular disease and cerebral changes in people with type 2 diabetes. In the general population, however, several studies have shown that macrovascular atherosclerotic disease is associated with age-related cognitive impairment and changes in brain MRI. In a large cross-sectional study, for example, previous vascular events, presence of plaques in the carotid arteries and presence of peripheral arterial atherosclerotic disease were negatively associated with cognitive performance \[[@CR17]\]. In another study, the association between the number of cardiovascular disease conditions and cognitive impairment appeared to show a 'dose--response' relationship \[[@CR18]\]. With regard to brain MRI changes, a history of stroke or myocardial infarction has been associated with the presence of WML \[[@CR19]\] and plaques in the carotid artery with PWML \[[@CR16], [@CR45]\].

The strength of our study is that we combined detailed data on cognitive function and brain MRI with detailed data on metabolic and vascular risk factor clusters, thus allowing an accurate assessment of the relation between these factors. Possible limitations include patient selection, the cross-sectional design and the large number of explanatory variables addressed. With regard to patient selection, we aimed to obtain a representative sample of functionally independent patients with type 2 diabetes from the general population. Although the rather demanding testing protocol may have deterred patients with relatively severe mental or physical limitations, the prevalence of microvascular and macrovascular disease, hypertension and smoking habits, as well as the level of metabolic control in our study sample is comparable with those found in other population-based studies in the Netherlands \[[@CR46]--[@CR48]\]. To minimise the effects of lifestyle and socioeconomic factors, control participants were recruited from the direct environment of the type 2 diabetic patients. Consently, the prevalence of risk factors such as hypertension and high BMI was higher than would be expected in the general population in the Netherlands. If anything, this would have decreased the differences in cognition and MRI ratings between the groups. The cross-sectional design of our study precludes inferences about causal relationships. Moreover, the cognitive and imaging outcome measures were probably influenced by a large number of factors, some of which are specific to type 2 diabetes mellitus (e.g. chronic hyperglycaemia, diabetes treatment) and some not (e.g. age, hypertension, atherosclerosis). Our exploratory analysis included a large number of explanatory variables, which has certain drawbacks. First, different explanatory variables might be interrelated. The relatively small regression coefficients and effect sizes affect the evaluation of these interrelations and limit statistical power. This may also explain why some of the variables that reached statistical significance in the univariate analyses dropped out of the multivariate model. Nevertheless, the multivariate analysis as presented in Table [5](#Tab5){ref-type="table"} does indicate which variables were the strongest independent determinants of cognition and MRI abnormalities in the model used. The second drawback is that the large number of regression analyses can lead to type I errors. Nevertheless, we feel that this first detailed study of cognition and brain MRI in type 2 diabetes patients in relation to metabolic and vascular risk factors does provide important leads that could be further evaluated in future studies. Such studies should: (1) preferably have a longitudinal design; (2) include assessment of cognition and brain MRI in relation to chronic hyperglycaemia and atherosclerotic vascular disease; and (3) allow the assessment of potential confounders (e.g. hypertension).

Type 2 diabetes is associated with modest impairments in cognition, as well as with atrophy and vascular lesions on MRI. This 'diabetic encephalopathy' is a multifactorial condition, for which atherosclerotic (macroangiopathic) vascular disease is an important determinant. Chronic hyperglycaemia, hypertension and hyperinsulinaemia may play additional roles.
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CIMT

:   carotid intima-media thickness

DWML

:   deep white matter lesions

FLAIR

:   fluid-attenuating inverse recovery

HOMA-IR

:   homeostasis model assessment of insulin resistance

MRI

:   magnetic resonance imaging

PWML

:   periventricular white matter lesions

WML

:   white matter lesions
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